Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
– Both trials met the primary and key secondary endpoints at the pre-specified interim analysis – – Data continue to demonstrate transformative and durable benefit – – Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant – BOSTON & ZUG,
